Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Seasonal Allergic Rhinitis: later-stage trial registry

A small indexed set (17 trials) with no open enrollment listed right now.

Corpus placement: #1,004 of 28,707 conditions by registered trial count.

17 US clinical trials · none currently recruiting · #1,004 of 28,707 conditions by registered trial count

Seasonal Allergic Rhinitis: 17 US clinical trials tracked, none currently recruiting.

Seasonal Allergic Rhinitis is the subject of 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 12 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Alcon Research, running 3 of these trials.

Enrollment posture brief

Registry condition seasonal-allergic-rhinitis

OPEN 0 | RECR 0% | LATE 12 | EARLY 4 | RANK #1004 | SPON 3

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Myeloid Leukemia, in R70.6%Abdominal Aortic Aneurysm52.9%Acute Lymphoblastic Leukemia23.5%Actinic Keratosis11.8%Seasonal Allergic Rhinit (th…0%
Open-enrollment share among volume-matched conditions near Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis has no open enrollment in this registry pull (17 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Seasonal Allergic Rhinitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Seasonal Allergic Rhinitis is recruiting below its size-band peers.

    0 of 17 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Seasonal Allergic Rhinitis research.

    Alcon Research accounts for 3 of 17 trials (17.6%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Typical Seasonal Allergic Rhinitis enrolment sits around 596 participants.

    Median target enrolment is 596 among the 17 trials that report a genuine target (sentinel values excluded). 2 of those (11.8%) plan for fewer than 100 participants.

  4. Seasonal Allergic Rhinitis research is mostly interventional.

    16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 36Phase 46

Indexed trials (enrollment closed)

17 total, page 1 of 1

COMPLETED Phase 3 2,388 participants

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

Alcon Research

NCT00578929

COMPLETED Phase 3 1,180 participants

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Glenmark Specialty S.A.

NCT02631551

COMPLETED Phase 4 1,010 participants

Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

Sanofi

NCT00637611

COMPLETED Phase 3 847 participants

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Sumitomo Pharma America

NCT01458275

COMPLETED Phase 3 776 participants

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Meda Pharmaceuticals

NCT00740792

COMPLETED Phase 3 715 participants

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Teva Branded Pharmaceutical Products R&D

NCT01307319

COMPLETED Phase 3 660 participants

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

AstraZeneca

NCT00305487

COMPLETED Phase 2 601 participants

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

Bausch & Lomb Incorporated

NCT01277341

COMPLETED Phase 4 596 participants

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

UCB Pharma

NCT00621959

COMPLETED Phase 4 580 participants

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

UCB Pharma

NCT00653224

COMPLETED Phase 2 579 participants

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

Idorsia Pharmaceuticals

NCT01241214

COMPLETED Phase 2 265 participants

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Allergy Therapeutics

NCT02582073

COMPLETED Phase 4 150 participants

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

Alcon Research

NCT00845195

COMPLETED Phase 4 130 participants

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

Alcon Research

NCT00691665

COMPLETED Phase 2 100 participants

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects

Magna Pharmaceuticals

NCT01171664

COMPLETED 92 participants

Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics

University of North Carolina, Chapel Hill

NCT04670627

COMPLETED Phase 4 20 participants

Intranasal Steroids and the Nasal Ocular Response

University of Chicago

NCT00473915

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 6
Phase 4 6

Named interventions

Most-linked intervention names on Seasonal Allergic Rhinitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

placebo Drug
3 trials
Placebo Drug
3 trials
levocetirizine dihydrochloride Drug
2 trials
ciclesonide nasal aerosol 74 mcg Drug
1 trials
Ciclesonide nasal aerosol 37 mcg Drug
1 trials
Olopatadine Hydrochloride Nasal Spray 0.6% Drug
1 trials
Azelastine HCl Nasal Spray, 0.1% Drug
1 trials
Olopatadine HCl Nasal Spray, 0.6% Drug
1 trials

US sites by state

Facility locations filed on Seasonal Allergic Rhinitis trials. A trial with sites in several states counts in each.

California 9 trials
Georgia 7 trials
Colorado 6 trials
New Jersey 4 trials
Minnesota 4 trials
Kentucky 4 trials
Illinois 4 trials
Texas 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Seasonal Allergic Rhinitis page

17 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Seasonal Allergic Rhinitis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Alcon Research sponsors the most Seasonal Allergic Rhinitis trials on record, review their full trial history before evaluating a specific study. See Alcon Research's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Seasonal Allergic Rhinitis condition card totals 17 registered trials; most-linked intervention placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.